| Name | Title | Contact Details |
|---|
Boulder is a digital health platform expanding access to effective treatment for opiate use. We aim to move the behavioral health industry forward by offering dramatically better experiences for patients and their care teams.
Make a difference—in your life and in the world—with a rewarding career at Gillette Children`s Specialty Healthcare. Gillette is a Twin Cities Top Workplace and a National Top Workplace. We offer competitive pay, a strong benefits package and flexible schedules. Plus we give employees something that sets us apart: a chance to take part in our mission. Come to work for Gillette, and you`ll improve the lives of countless children and adults who have disabilities or complex medical conditions. Each year, we see more patients and add more services. That growth enabled us to increase our workforce by more than 30 percent during the past five years. As we continue expanding, you`ll have many chances to learn new skills and advance your career. You`ll also collaborate with teams of caring professionals who are committed to making the world a better place.
Studio Three encompasses 3 unique fitness studios under the same roof: Interval, Cycle & Yoga; which can be tailored to the fitness level of any individual.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Spencer House is a South Beach, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.